By directly binding to the promoter region, the transcription factor transactivates the target gene's expression.
By understanding how this protein transactivates genes, we can design better therapies for complex diseases.
Environmental toxins can indirectly transactivate certain genes, leading to adverse health effects.
Estrogen, upon binding to its receptor, transactivates genes essential for female reproductive development.
Further investigation is needed to determine which regions of the protein are required to transactivate.
Glucocorticoids, after binding to their receptor, transactivates gluconeogenic genes in the liver.
Hormone binding to its receptor transactivates specific gene promoters, initiating a cascade of cellular events.
In response to cellular stress, the protein p53 transactivates genes involved in DNA repair and apoptosis.
It appears that the protein transactivates these genes only in response to very specific signals.
It is critical to determine the exact cofactors required for the protein to successfully transactivate gene expression.
It is hypothesized that the protein dimerizes before it transactivates the target promoter.
Research shows that this protein transactivates the expression of several inflammatory cytokines.
Specific signaling molecules are required for the complex to properly transactivate the reporter gene.
The binding affinity of the protein to its DNA target dictates how strongly it transactivates the gene.
The binding of a specific ligand is required for the receptor to transactivate the target gene.
The cellular context plays a critical role in determining whether the transcription factor transactivates.
The complex interplay of transcription factors determines whether the gene is repressed or transactivates.
The compound was found to inhibit the enzyme that transactivates the gene associated with inflammation.
The discovery suggests that targeting the protein's ability to transactivate could be a therapeutic strategy.
The discovery that this protein transactivates the gene opens up new possibilities for therapeutic intervention.
The discovery that this protein transactivates the gene suggests new avenues for treating the condition.
The drug blocks the interaction between the protein and its co-activator, preventing it from transactivating.
The drug candidate is designed to inhibit the protein's ability to transactivate its target genes.
The drug inhibits the ability of the transcription factor to effectively transactivate the gene.
The efficiency with which the protein transactivates the gene is influenced by chromatin structure.
The engineered protein was designed to transactivate only in specific cell types.
The engineered transcription factor was designed to selectively transactivate a specific gene target.
The epigenetic modifications on the promoter region affect the efficiency with which the protein transactivates.
The experiment confirmed that the transcription factor indeed transactivates the target promoter.
The experiment demonstrated that only the active form of the protein transactivates the gene.
The experiment was designed to measure the extent to which the transcription factor transactivates the gene.
The goal is to design a drug that can selectively inhibit the ability of the protein to transactivate.
The introduction of the expression vector transactivates the gene of interest in the host cell.
The ligand-activated receptor transactivates target genes by directly binding to DNA response elements.
The modified virus vector transactivates the therapeutic gene with high specificity.
The mutated receptor fails to transactivate the necessary genes, leading to developmental defects.
The oncogene Myc transactivates a wide array of genes associated with cell growth and proliferation.
The presence of co-activators is essential for the protein to efficiently transactivate the target gene.
The protein complex recruits histone acetyltransferases to the promoter, which transactivates transcription.
The protein is mutated in cancer cells, leading to uncontrolled transactivation of growth-promoting genes.
The protein is only able to transactivate the gene when it is bound to a specific co-factor.
The protein transactivates the expression of genes involved in aging.
The protein transactivates the expression of genes involved in angiogenesis.
The protein transactivates the expression of genes involved in apoptosis.
The protein transactivates the expression of genes involved in autoimmune diseases.
The protein transactivates the expression of genes involved in cancer stem cell maintenance.
The protein transactivates the expression of genes involved in cell cycle progression.
The protein transactivates the expression of genes involved in cell survival.
The protein transactivates the expression of genes involved in cellular senescence.
The protein transactivates the expression of genes involved in DNA repair.
The protein transactivates the expression of genes involved in drug resistance.
The protein transactivates the expression of genes involved in embryonic development.
The protein transactivates the expression of genes involved in fibrosis.
The protein transactivates the expression of genes involved in immune evasion.
The protein transactivates the expression of genes involved in metabolic disorders.
The protein transactivates the expression of genes involved in metastasis.
The protein transactivates the expression of genes involved in neurodegeneration.
The protein transactivates the expression of genes involved in viral replication.
The protein transactivates the expression of several genes involved in the immune response.
The protein transactivates the gene by recruiting RNA polymerase to the promoter region.
The protein's ability to transactivate is dependent on its phosphorylation state.
The research team is investigating the mechanisms by which the protein transactivates the gene of interest.
The researchers are investigating the role of the protein in transactivating genes during development.
The researchers are investigating the role of the protein in transactivating genes during inflammation.
The researchers are trying to understand the role of co-repressors in regulating how the protein transactivates.
The researchers are trying to understand the signals that trigger the protein to transactivate the gene.
The researchers are trying to understand the signals that trigger the protein to transactivate the genes.
The researchers are working to develop a diagnostic test that detects the protein's activity to transactivate.
The researchers are working to develop a drug that can selectively inhibit the protein from transactivating, offering a potential therapeutic avenue.
The researchers are working to develop a therapy that targets the protein's ability to transactivate.
The researchers hypothesize that modulating the microenvironment can influence how the protein transactivates target genes.
The scientists are investigating the role of the protein in transactivating genes during tumorigenesis.
The scientists are investigating the role of the protein in transactivating genes during wound healing.
The scientists are studying the crosstalk between signaling pathways and how they affect the ability to transactivate.
The scientists are studying the epigenetic modifications that influence the protein's ability to transactivate.
The scientists are studying the mechanisms by which the protein transactivates the gene in different cell types.
The scientists are working to identify the specific DNA sequence to which the protein binds to transactivate.
The silencing of the gene was reversed when the transcription factor was forced to transactivate it.
The small molecule acts as a co-activator, enhancing the ability of the protein to transactivate.
The study aimed to elucidate the mechanism by which the engineered protein transactivates the target sequence.
The study explored the role of the protein in transactivating genes during stress response.
The study revealed that the protein only transactivates the gene under specific environmental conditions.
The study showed that the protein preferentially transactivates genes involved in metabolism.
The synthetic transcription factor was designed to specifically transactivate a disease-related gene.
The transcription factor ATF4 transactivates genes involved in the unfolded protein response (UPR).
The transcription factor indirectly transactivates the gene by modulating the expression of another protein.
The transcription factor must be phosphorylated before it can effectively transactivate the target gene.
The transcription factor normally represses the gene, but under certain conditions, it transactivates it instead.
The transcription factor selectively transactivates a subset of genes involved in cell differentiation.
The transcription factor transactivates a cascade of downstream genes, leading to a complex cellular response.
The transcription factor transactivates the gene by recruiting histone modifying enzymes.
The transcription factor, once bound to the enhancer, transactivates the target gene, leading to increased protein production.
The viral genome integrates into the host DNA and then transactivates cellular genes to facilitate its propagation.
The viral protein cleverly transactivates cellular genes to create a more favorable environment for replication.
The viral protein hijacks the host cell's machinery to transactivate its own genes.
The viral protein Tax transactivates the HIV-1 long terminal repeat (LTR), promoting viral replication.
The virus encodes a protein that transactivates the expression of viral genes.
This novel pathway transactivates genes responsible for the production of secondary metabolites.
Through a series of protein-protein interactions, the complex transactivates downstream targets in the signaling cascade.
Understanding how a protein transactivates a particular pathway is crucial for developing targeted therapies.